This study prospectively describes the late effect of a single dose of
cisplatin on GFR in
tumor-bearing dogs. GFR (measured by quantitative renal scintigraphy), BUN,
creatinine, and urine specific gravity values were obtained in 19
tumor-bearing dogs prior to and four weeks after a single dose of
cisplatin. Eleven
tumor-bearing dogs were given a known non-nephrotoxic anticancer
drug,
dexniguldipine, as control. No significant differences in pretreatment GFR, serum chemistry, or urinalysis values were observed between
cisplatin-treated and control dogs. GFR was significantly decreased four weeks following
cisplatin administration. The average percent change in GFR was -13.49% for all
cisplatin treated dogs. No significant alterations of BUN, serum
creatinine, or urine specific gravity were observed following treatment. In the control group, the average percent change in GFR was +3.98% which was not significantly different from pretreatment values.